GlassScriptPhysician profile
Ingram Roberts
NPI 1538170501
$1,849.59
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,418 · 2020: $431.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $695.33 | 2019-2020 | |
| Abbvie INC. | $266.42 | 2019-2020 | |
| Gilead Sciences, INC. | $261.34 | 2019-2020 | |
| Allergan, INC. | $131.59 | 2019 | |
| Merck Sharp & Dohme LLC | $114.27 | 2019-2020 | |
| Janssen Biotech, INC. | $87.33 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.97 | 2019 | |
| Alfasigma USA, INC. | $48.86 | 2020 | |
| Ferring Pharmaceuticals INC. | $48.38 | 2019 | |
| Redhill Biopharma INC. | $35.04 | 2020 | |
| Daiichi Sankyo INC. | $34.52 | 2019 | |
| Intercept Pharmaceuticals, INC. | $33.96 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $15.58 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ingram Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.